Chemistry:Velmanase alfa
From HandWiki
| Clinical data | |
|---|---|
| Trade names | Lamzede |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Velmanase alfa, sold under the brand name Lamzede, is a medication for the treatment of alpha-mannosidosis.[1][2]
Velmanase alfa is a recombinant form of human alpha-mannosidase.[3]
Velmanase alfa was approved for medical use in the European Union in March 2018.[1][3]
References
- ↑ 1.0 1.1 1.2 "Lamzede EPAR". https://www.ema.europa.eu/en/medicines/human/EPAR/lamzede.
- ↑ "Alpha-Mannosidosis". GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. July 2019. https://www.ncbi.nlm.nih.gov/books/NBK1396/.
- ↑ 3.0 3.1 "Chiesi Group receives the European Marketing Authorisation for Lamzede" (Press release). 4 April 2018. Retrieved 24 August 2020.
External links
- "Velmanase Alfa". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/rn/9025-42-7.
- alpha-Mannosidase at the US National Library of Medicine Medical Subject Headings (MeSH)
 |  |
